We have recently welcomed three new Principals to join our team across New York, Switzerland, and New Jersey. They are highly experienced and talented professionals who will bring a wealth of expertise to our team and clients.
Please join us in welcoming the following new Principals to our team:
Shrividya (Shri) Iyer has joined our Value, Pricing & Access practice area. Shri has 20+ years’ experience in the pharmaceutical industry, building and leading global health economics outcomes research (HEOR)/ RWE teams across diverse therapeutic areas. In her most recent role, Shri was Executive Director, Oncology Worldwide Real-World Evidence and US HEOR with Eisai, Inc. Shri has expertise and extensive experience in developing and executing a comprehensive HEOR strategy including clinical, patient reported, economic outcomes and RWE related to pipeline, launch and marketed products meeting the needs of diverse health care stakeholders worldwide including regulators, HTAs, payers/policymakers, HCPs and clinical pathway developers. Shri has published extensively in leading peer reviewed scientific journals with reputed KOLs/investigators and presented at clinical and HEOR conferences worldwide. Shri has a PhD in pharmaceutical socioeconomics from the University of Iowa, USA, a degree in pharmacy from University of Mumbai, India and a Certificate in Business Excellence in Digital Health from the Columbia Business School, New York.
Shri was eager to join Putnam for the opportunity to learn and evolve on the consulting side while continuing to blend science and strategy to add meaningful value to life sciences.
Naveen Venkataraman is joining Putnam part of the Commercial strategy practice and will be based in Basel, Switzerland. Prior to joining Putnam, Naveen served as a Director on the Life Sciences Consulting team at EY, advising clients in the US and Europe on a range of commercial strategy and transformation topics. He has experience in market opportunity evaluations, commercial excellence and operating models, competitive analysis, digital strategy, and post-merger integration for major biopharma and biotech clients. His TA experience covers oncology, hematology, and vaccines. Naveen has extensive international experience working in Europe, the US, Japan, and the Middle East. He has an MBA in Marketing from Babson College and a bachelor’s in engineering from the University of Bombay.
Naveen is most excited to work with the leadership team in growing our European business to serve clients with differentiated service offerings and to collaborate with our talented team members.
Mohan Chukkapalli will be joining the Commercial practice, focused on early commercialization. He’ll be working with the India (Gurgaon)-based team, although he is based in New Jersey. He comes to us with an academic background in Pharmacy with a bachelor’s degree in Pharmaceutical Sciences from Kakatiya University and a Master’s in Pharmaceutical Marketing from the University of Mississippi, as well as a tenured career in strategy consulting. Over the last decade, Mohan was an Executive Director at SmartAnalyst Inc, and spent the last year at Envision Pharma. His functional focus has been disease area strategy, early-stage asset/indication prioritization, life-cycle management, pre-launch competitive assessment, positioning, and BD&L valuation. Prior to consulting, Mohan spent 10+ years on the client side working in business development and strategic marketing at King Pharmaceuticals (Pfizer), Imclone Systems Inc (now Eli Lilly), Novo Nordisk, Hoffmann-La Roche and Bayer.
Mohan is looking forward to coming back to Putnam, reconnecting with new colleagues and establishing new relationships internally and externally.